Onset:

• Gum (Nicorette 2 mg / 4 mg): 5-15 min for buccal absorption peak; "park" between cheek and gum after 10-15 chews, NOT chew continuously. Tmax ~30 min.
• Lozenge (2 mg / 4 mg): Similar to gum, 10-20 min. Slightly more uniform absorption.
• Patch (7 / 14 / 21 mg/24h): Slow onset (1-2h to plasma peak), sustained delivery over 16-24h. Patch is the lowest-dependence form because the slow rise eliminates the reward-pulse signal that drives addiction.
• Pouch (Zyn, On!, etc.): 2-5 min onset (sublabial absorption is fast). HIGH dependence form — the rapid pulse + cue-conditioning availability is the worst combination.
• Vape: 1-3 min onset, alveolar absorption competing with smoking for fastest delivery. EXTREME dependence form — never use for nootropic purpose.
• Smoke: ~10 seconds to brain. Highest reinforcement schedule, highest dependence. Off the table for nootropic use; mentioned only for completeness.

Peak (gum 2 mg in nicotine-naive Dylan-archetype):

• Sharp uptick in alertness within 10-15 min. Subjective "wake up" — comparable to caffeine 100mg in onset but with a different qualitative texture: caffeine has more arousal/sympathetic edge; nicotine has more cognitive sharpness + mild anxiolytic warmth.
• Mild mouth tingling, slight throat scratch.
• Mild HR rise (5-10 bpm), mild BP rise (3-8 mmHg systolic).
• Possible first-time nausea — α3β4 ganglionic + medullary effect; usually resolves with subsequent doses or smaller doses (start at 2 mg, never 4 mg for naive).
• Cognitive feel: faster context switching, easier to maintain focus on a single task, slight reduction in "background mental noise."
• Mood: mild lift, mild anxiolytic effect at low dose. (At higher dose 4+ mg in naive, can flip to mild anxiety/jitter.)
• Mild appetite suppression (lasts ~1-2 hours post-dose).

Plateau: 30-60 min of clear cognitive runway at gum 2 mg; longer (2-3 hours) at patch 7-14 mg; 12+ hours at patch 21 mg.

Taper:

• Gum/lozenge: 60-90 min to baseline.
• Patch: gradual taper over the patch wear period (usually removed at bedtime to avoid sleep disruption — see Side Effects).

Honest variability: Some users (~15-25%) get strong nausea + dysphoria on first exposure, find no cognitive benefit, and stop. Some get strong euphoria + reward signal that predicts higher dependence trajectory (these users should NOT continue — the "I really like this" response is the warning sign). Most users sit in the middle — mild benefit, mild side effects, gradual creep toward more frequent use if not actively guarded against.

The dependence-warning subjective signature: When someone says "this is my favorite nootropic" + "I find myself reaching for the gum without thinking" + "I notice I'm using it more than I planned" — that's the cue-conditioning + reward-loop forming. For Dylan, watch for any of these signals and stop immediately if they appear.

• Tolerance buildup: VERY FAST for some effects, slower for others.

  • Acute nausea / dizziness: tolerance develops within hours-to-days.
  • Cognitive effect: tolerance develops over days-to-weeks of regular use, but the alerting/attention effect persists in dependent smokers (which is why people keep smoking — the effect doesn't fully tolerate).
  • Reward signal (the dependence-forming one): tolerance develops fast at the receptor level (α4β2 desensitization + upregulation) but the conditioned cue-response gets STRONGER over time, not weaker. This is the asymmetry that traps users.

• Recommended cycle for Dylan-archetype (if used at all): PRN-only, max 1-2 days per week, with mandatory 4-week complete abstinence after every 8-week PRN block to detect any dependence creep. If craving emerges during abstinence, escalate to permanent SKIP.

• Reset protocol: 4 weeks of complete abstinence is sufficient for receptor renormalization + cue-conditioning extinction, IF the user has been strictly PRN. Daily users need 8-12+ weeks for similar reset and many never fully recover from the cue-conditioning (the pattern stays latent for years).

• Why nicotine is structurally different from caffeine on cycling: Caffeine's tolerance is a pharmacokinetic + receptor-density phenomenon — reset works cleanly. Nicotine's tolerance has the same pharmacokinetic component PLUS a learning/conditioning component that doesn't reset just by waiting. The brain remembers the reward-pairing, and re-exposure can re-trigger the full dependence pattern faster than the original onboarding. This is why ex-smokers can relapse after 10+ years of abstinence on a single re-exposure.

Synergistic with

• None recommended for Dylan. The synergies that exist (nicotine + caffeine for additional alerting, nicotine + tyrosine for sustained DA support) all increase the cardiovascular/sympathetic load + the daily-tool gravitational pull without providing benefit that other PRN combinations can't deliver. Don't stack a watch-list compound to extract more benefit; stack only the safer alternatives.

• Theoretical (not recommended in practice):

  • Caffeine + nicotine: additive alerting + cognitive performance. Cardiovascular load + dependence reinforcement also additive. Skip.
  • Tyrosine + nicotine: mechanistic synergy via DA precursor + nAChR-mediated DA release. Dylan can get the same effect from caffeine + tyrosine without the dependence vector.

Avoid stacking with

• Other stimulants (caffeine, modafinil, amphetamine, methylphenidate) — cumulative HR/BP/sympathetic load. Anxiety + arrhythmia risk superlinear. Cardiovascular safety margin in 20yo is wide but it's not the right use of the safety margin.
• High-dose AChEIs (galantamine, donepezil, huperzine A) — additive cholinergic load, GI distress, possible bradycardia at the periphery (nicotine drives HR up while AChEI drives HR down — net is unpredictable + uncomfortable).
• Beta-blockers (propranolol) — masks the HR signal that's the early-warning for over-dosing. Functional but not recommended for nootropic stacking.
• CYP1A2 substrates — smoking induces CYP1A2 and accelerates clearance of caffeine, theophylline, clozapine, olanzapine. Gum/lozenge/patch routes do NOT induce CYP1A2 (the induction comes from polycyclic aromatic hydrocarbons in smoke, not from nicotine itself). So gum/patch users don't have the smoker-style accelerated caffeine metabolism.

Neutral / safe co-administration

• All Dylan's V4 supplements (Mg, NAC, citicoline, PS, DHA, curcumin, rhodiola, theanine, glycine/tryptophan, D3/K2, beta-alanine, vitamin C) — no pharmacological interactions of concern. Theanine specifically can blunt nicotine's anxiety/jitter at higher doses, similar to its caffeine effect.

Nicotine's metabolic profile:

• Primarily metabolized by hepatic CYP2A6 (~80% of nicotine clearance, to cotinine and then to trans-3'-hydroxycotinine).
• Minor pathways: CYP2B6, FMO3, UGT2B10.
• CYP2A6 polymorphism is the dominant pharmacogenomic axis (see Pharmacogenomics).

Smoking-induced CYP1A2 (route-dependent, not nicotine-dependent):

• Cigarette smoke induces CYP1A2 via PAH-mediated AHR activation — this accelerates clearance of caffeine, theophylline, clozapine, olanzapine, tacrine, ropinirole, etc.
• Nicotine gum/lozenge/patch DO NOT induce CYP1A2 because the induction signal is the PAH content of smoke, not nicotine itself. This is clinically important: a smoker who switches to gum will see caffeine half-life lengthen back to non-smoker baseline within 1-2 weeks, and may need to halve caffeine dose to avoid jitter/insomnia. Not relevant for Dylan-direct (he's never smoked) but worth noting in this file.

Clinically significant interactions:

1. CYP2A6 inhibitors (methoxsalen, tryptamine, some grapefruit components — though grapefruit-CYP2A6 interaction is weaker than with CYP3A4) — can prolong nicotine half-life. Generally not clinically significant at PRN gum doses.
2. MAOIs — tobacco smoke contains MAO inhibitors (harman, norharman) that contribute to smoking's dopaminergic profile. Pure nicotine (gum/patch) does not contain these — nicotine alone is a weaker dopaminergic than smoking is. This is a pro for nootropic gum/patch use (less dependence) but means subjective experience differs from cigarettes.
3. Beta-blockers — mask early HR signal (see Stacking).
4. Insulin — nicotine can transiently raise blood glucose via sympathetic activation; relevant in diabetics, not Dylan.
5. Warfarin — smoking-induced CYP1A2 affects warfarin clearance; gum/patch route does not.
6. Caffeine — additive sympathetic load; co-substrate-of-different-enzymes so no PK interaction at gum/patch.

CYP2A6 (the dominant variant for nicotine metabolism):

• Normal metabolizer (most common alleles, e.g., CYP2A6*1): Half-life ~2 hours. Standard dosing.
• Slow metabolizer (CYP2A6*2, *4, *9, *12 variants): Half-life 3-5+ hours. Higher exposure per dose, longer subjective effect, lower dependence trajectory (slower clearance = less reward-pulse signal that drives addiction). Slow metabolizers smoke fewer cigarettes per day in epidemiology data. For nootropic gum use: slow metabolizers may need only 1 mg or half a 2 mg gum for the same effect; longer cognitive runway from a single dose.
• Ultra-rapid metabolizer (rare CYP2A6 duplications): Half-life <1.5h. Higher cigarettes per day in epi data. Faster dependence escalation at the same exposure pattern.
• Dylan's 23andMe (~June 5-15, 2026) can extract CYP2A6 status. Regardless of phenotype, the verdict for Dylan stays WATCH-LIST — slow-metabolizer status mitigates dependence risk somewhat but doesn't change the adolescent-brain risk or the existence-of-cleaner-alternatives argument.

CHRNA4 rs1044396 (α4 nAChR subunit polymorphism):

• Affects α4β2 receptor function and nicotine reinforcement strength.
• Some alleles associated with stronger reward signal + faster dependence onset.
• 23andMe raw data via Promethease can extract.

CHRNA5/CHRNA3/CHRNB4 cluster (chr 15):

• Strongest GWAS signals for nicotine dependence + lung cancer + heavy smoking.
• rs16969968 (CHRNA5 D398N) variant carriers have ~30% higher dependence rates per allele.
• For Dylan: if this variant is present, dependence risk is elevated baseline → permanent SKIP becomes more reasonable.

Practical pre-23andMe recommendation for Dylan:

• Default assumption: normal metabolizer + average dependence risk.
• Verdict stays WATCH-LIST regardless of phenotype at age 20.
• If 23andMe shows CHRNA5 rs16969968 risk allele or CHRNA4 high-reward variant: shift to permanent SKIP.
• If 23andMe shows CYP2A6 slow metabolizer: still WATCH-LIST, but if used, half-dose (1 mg gum or split).

For Dylan: if used at all, 2 mg gum from any reputable OTC source (Nicorette generic, Amazon basics nicotine gum, drugstore brand). Buy small box (20-50 pieces), NOT bulk — limit availability is a soft barrier against habit creep.

Baseline (before starting, if Dylan ever does)

• Resting HR + BP (3-day morning average) — establish pre-nicotine baseline.
• Anxiety baseline (GAD-7 or daily 1-10 VAS).
• Subjective cognitive performance VAS (1-10) for 7 days pre-dose.
• Dependence VAS — "do you ever crave nicotine right now?" — must be 0/10 baseline.
• 23andMe pharmacogenomics (CYP2A6, CHRNA4, CHRNA5) — pre-trial check for high-risk variants.

During use (the most important tracking section in this entire file)

• Daily craving VAS — "do you want a piece of gum right now even outside the planned session?" If >0 on any day, that's the dependence signal forming. Stop immediately.
• Weekly dose count — number of gum pieces / lozenges this week. Pre-commit to a hard cap (e.g., 4 pieces/week max). If you hit the cap, you're already at the limit; don't expand.
• Cue-association journaling — "did I dose because of the planned task, or because of a contextual trigger (coffee, social, stress)?" If contextual triggers start showing up, cue-conditioning is forming.
• HR/BP weekly — verify cardiovascular signal stays modest.
• Anxiety daily VAS — baseline → on-day → off-day comparison. Watch for "I'm calmer when I dose" signal — that's the anxiolytic dependence pattern.

Post-cycle (mandatory abstinence period, every 8 weeks)

• Day 1-3 craving VAS: any craving = dependence forming. Severity scales with dependence depth.
• Day 1-7 sleep, mood, anxiety tracking. Acute withdrawal symptoms appear here in dependent users.
• Day 14 cognitive performance VAS vs. on-cycle average. If "I can't focus without it" emerges, that's withdrawal-reversal masquerading as cognitive enhancement.
• Day 28 craving check. If craving has resolved fully, the cycle was healthy and Dylan can re-evaluate continuation. If craving persists, switch to permanent SKIP.